Initiation of a Once Daily Regimen of Tenofovir, Lamivudine and Efavirenz After 4 Weeks Versus 12 Weeks of Tuberculosis Treatment in HIV-1 Infected Patients (Time Study).

Trial Profile

Initiation of a Once Daily Regimen of Tenofovir, Lamivudine and Efavirenz After 4 Weeks Versus 12 Weeks of Tuberculosis Treatment in HIV-1 Infected Patients (Time Study).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 15 May 2012

At a glance

  • Drugs Efavirenz; Lamivudine; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TIME
  • Most Recent Events

    • 15 May 2012 Results published in the Journal of Acquired Immune Deficiency Syndromes (1999).
    • 16 Nov 2011 Planned End Date changed from 1 Oct 2013 to 1 May 2011 as reported by ClinicalTrials.gov.
    • 16 Nov 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top